Complementary medicine to reduce stiffness
- Trial ID
- NCT07207096
- Official Title
- Observational Case Series of Patients With Parkinson's Disease (PD) Attending a Complementary Medicine Neuro-degenerative Disease (NDD) Clinic.
- Goal
- Complementary medicine to reduce stiffness
- Status
- RECRUITING
- Sponsor
- St. Mary's University, Twickenham
- Study Type
- OBSERVATIONAL
- Enrollment
- 100 participants
- Conditions
- Parkinson Disease, Parkinsonism
- Interventions
- complementary medicine
Plain-Language Summary
The goal is to track how people with Parkinson's disease or Parkinsonism do when they attend a complementary medicine neurodegenerative clinic, looking at symptom changes, safety, and quality of life over time. The approach is observational, recording which complementary therapies are used, for example tailored lifestyle and rehabilitation plans, acupuncture or other manual therapies, nutritional or herbal supplements, and mind-body approaches, and measuring how those treatments affect mobility, sleep, mood, pain and medication side effects; these therapies are provided alongside standard drugs like levodopa rather than replacing them, and the study will note any interactions or safety signals. Eligibility is adults 18 and older with a self-reported diagnosis of Parkinson's disease or Parkinsonism, excluding people who need acute medical care or who have another neurodegenerative diagnosis, and excluding those without a PD/Parkinsonism diagnosis even if they are at risk.
Locations
- Feldy Community Centre, London, United Kingdom
Frequently Asked Questions
- What is this trial testing?
- This trial is studying complementary medicine. The goal is to track how people with Parkinson's disease or Parkinsonism do when they attend a complementary medicine neurodegenerative clinic, looking at symptom changes, safety, and quality of life over time. The approach is observational, recording which complementary therapies are used, for example tailored lifestyle and rehabilitation plans, acupuncture or other manual therapies, nutritional or herbal supplements, and mind-body approaches, and measuring how those treatments affect mobility, sleep, mood, pain and medication side effects; these therapies are provided alongside standard drugs like levodopa rather than replacing them, and the study will note any interactions or safety signals. Eligibility is adults 18 and older with a self-reported diagnosis of Parkinson's disease or Parkinsonism, excluding people who need acute medical care or who have another neurodegenerative diagnosis, and excluding those without a PD/Parkinsonism diagnosis even if they are at risk.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 11 months.